Mosliciguat
Idiopathic Pulmonary Fibrosis · ANZCTR
Clinical trials
1
Mechanism
ANZCTR
Developer
Pulmovant, Inc.
Overview
Mosliciguat is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via anzctr. It appears in 1 tracked IPF clinical trial.
Mosliciguat clinical trials
Explore related
Medical disclaimer. This page summarizes research about Mosliciguat for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.